Sage Therapeutics, Inc. (SAGE) financial statements (2021 and earlier)

Company profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,1001,008923519397187128
Cash and cash equivalents1,661127191306169187128
Short-term investments438882732213229  
Deferred costs     0 
Other undisclosed current assets2327226521
Total current assets:2,1221,035945525403188129
Noncurrent Assets
Operating lease, right-of-use asset2534
Property, plant and equipment7964100
Restricted cash and investments2221100
Other noncurrent assets34     
Other undisclosed noncurrent assets     01
Total noncurrent assets:374985211
TOTAL ASSETS:2,1591,084953530405189130
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities59102865235158
Accounts payable4153491352
Accrued liabilities5587524322105
Employee-related liabilities      1
Debt 10     
Deferred tax liabilities    1
Other undisclosed current liabilities9     (1)
Total current liabilities:67112865235158
Noncurrent Liabilities
Long-term debt and lease obligation1927     
Operating lease, liability1927
Liabilities, other than long-term debt0143100
Other liabilities0143100
Total noncurrent liabilities:202743100
Total liabilities:87139905436158
Stockholders' equity
Stockholders' equity attributable to parent2,072945863475369174122
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)  
Additional paid in capital3,1102,5871,8271,066689335189
Accumulated other comprehensive income (loss)01(1)(0)(0)  
Accumulated deficit(1,037)(1,644)(963)(590)(320)(161)(67)
Total stockholders' equity:2,072945863475369174122
TOTAL LIABILITIES AND EQUITY:2,1591,084953530405189130

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:1,114790    
Operating expenses(518)(715)(484)(273)(160)(95)(34)
Operating income (loss):596(708)(393)(273)(160)(95)(34)
Nonoperating income (expense)(1)710(0)(0)(0)(0)
Investment income, nonoperating(1)710    
Other nonoperating income (expense)000(0)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes11      
Income (loss) before gain (loss) on sale of properties:606(701)(383)(273)(160)(95)(34)
Other undisclosed net income 2110    
Net income (loss):606(680)(373)(273)(160)(95)(34)
Other undisclosed net income attributable to parent   3100
Net income (loss) attributable to parent:606(680)(373)(270)(159)(94)(34)
Preferred stock dividends and other adjustments      (2)
Net income (loss) available to common stockholders, diluted:606(680)(373)(270)(159)(94)(36)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):606(680)(373)(273)(160)(95)(34)
Other comprehensive income (loss)(1)2(0)0(0)  
Comprehensive income (loss):605(678)(373)(273)(160)(95)(34)
Other undisclosed comprehensive income, net of tax, attributable to parent   31  
Comprehensive income (loss), net of tax, attributable to parent:605(678)(373)(270)(159)(95)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: